Background
In the 46 years since its discovery, the ubiquitous Epstein-Barr Virus (EBV) has been found to be closely associated with a wide range of epithelial and lymphoid malignancies [
1]. During all typical forms of latent EBV infection and B-cell immortalisation, two highly expressed gene products are the non-polyadenylated RNAs, Epstein-Barr Virus encoded RNAs 1 and 2 (EBER1 and EBER2). Although no definitive role for the EBERs in cell transformation or malignant growth has been elucidated, several studies highlight the EBERs as making a significant contribution to EBV-associated malignancies [
2‐
5] probably through direct interactions with cellular proteins with which they are known to form complexes. These include PKR [
6,
7], RIG-I [
8], La [
9] and ribosomal protein L22 [
10‐
12]. In addition, the EBERs can induce a number of cytokines in lymphocytes [
13,
14] and insulin-like growth factor 1 in epithelial cells [
15,
16]. Induction of these autocrine growth factors hints at the transforming role the EBERs may play in EBV pathology. Indeed, stable expression of EBERs in immortalised nasopharyngeal epithelial cells confers resistance to apoptotic stress [
17].
EBER1 and EBER2 are transcribed from the EBV genome by RNA polymerase III (pol III) and as such contain elements (intragenic A and B boxes) typical of those required for pol III transcription [
18,
19]. Interestingly, both EBER genes also possess upstream transcriptional regulatory regions that are more typical of pol II promoters; ATF, Sp1 and TATA binding sites [
20]. In addition, c-Myc has been shown to bind
in vitro and
in vivo to two E-Boxes upstream of the EBER1 gene and, in the context of a minimal promoter, the isolated Myc-binding locus was transcriptionally active in the presence of c-Myc [
21].
Several oncogenic viruses including hepatitis B virus, human T-cell leukaemia virus type 1, adenovirus, polyoma and SV40, stimulate RNA polymerase III-mediated transcription by the induction of increased levels of pol III-specific transcription factors [
22‐
26] and a number of trans-acting factors are known to be important in the transcriptional control of the EBERs [
2,
9,
27,
28]. Recently, EBV has been shown to induce the cellular transcription factors TFIIIB and TFIIIC (leading to induction of general pol III-mediated transcription) and the typical pol II transcription factor ATF-2, that enhance expression of EBER1 and EBER2 [
29].
Following EBV infection of B-lymphocytes, temporally the EBERs are the last EBV latent gene product to be expressed [
28,
30]. The aforementioned observations make it tempting to propose that another EBV latent gene product may be involved in the regulation of EBER expression through the induction of EBER-specific transcription factors. Indeed, evidence of such a phenomenon is found in our previous study which demonstrated the ability of EBNA1 to induce both the transcription of the genes and activity of the proteins of members of the AP-1 family, including ATF-2 [
31]. EBNA1 is also known to have transcriptional regulatory properties on the viral Cp, Qp and LMP1 promoters [
32‐
34].
Although the precise mechanisms by which EBERs may function in oncogenesis are not yet resolved, it is clear that they are an important component of the EBV latent gene complement. In this study, we aim to pinpoint the mechanisms by which EBV is able to increase EBER expression through induction of transcriptional components. Specifically, we test the hypothesis that EBNA1 may be the latent gene product involved in the regulation of both classic pol II and pol III transcription factors associated with EBER expression. Our results confirm the hypothesis and define additional EBNA1-mediated mechanisms of transcriptional regulation.
Discussion
It has long been established that high levels of EBER expression are a feature of cells latently infected with EBV and in cells of EBV-associated malignancies [
18]. The findings presented here provide evidence that EBNA1 plays a significant role in the regulation of EBER expression in epithelial cells. We show that EBNA1, like the adenovirus E1A protein [
24] and the T-antigens of polyomaviruses [
22,
25], increases cellular pol III transcription and induces expression of specific TFIIIC subunits. In addition, other EBER-associated transcription factors, ATF-2 and c-Myc, are shown to be transcriptionally upregulated, with EBNA1 being present at the promoters both of these genes and those of TFIIIC subunits. EBER expression is shown to be adversely affected by reduction of ATF-2 and c-Myc, highlighting the significance of EBNA1's ability to induce these transcription factors. Furthermore, EBNA1 was shown to enhance levels of EBER expression, illustrating its importance in the characteristic abundant expression of EBERs that is associated with EBV latent infection.
Our findings build upon our previous study [
29] which demonstrated that cellular pol III transcription and TFIIIC are induced in EBV-infected epithelial cells. The significance of increased levels of cellular pol III transcription is not restricted to increased levels of viral transcripts such as the EBERs. It is well-established that pol III transcription is often deregulated in a wide range of malignant tumours and transformed cells [
38,
42‐
44]. Furthermore, recent data suggest that increased pol III transcription is necessary or even sufficient to promote proliferation and oncogenic transformation in some contexts [
38,
45]. Our
in vivo findings support the idea of increased pol III transcription in malignant tumours, where induction of pol III-specific transcription factors was observed in NPC tumour samples at both the mRNA and protein level. Given our evidence for induction of TFIIIC subunits in EBNA1-expressing epithelial cells, and the well-established association between EBV and NPC, it is tempting to speculate that increased TFIIIC subunit levels in NPC tumour cells could be mediated, at least in part, by EBNA1.
Our data also address EBNA1's role in upregulation of the transcription factor ATF-2 that has previously been shown to be important for expression of EBERs [
20,
46,
47]. Earlier studies are conflicting in their descriptions of the effect of EBV on ATF-2. Initial studies revealed that EBV triggers hyperphosphorylation of ATF-2 leading to increased activity [
1,
48‐
51], with increased levels of mono-phosphorylated ATF-2 being observed in the absence of any increase in total levels of ATF-2. However, recent data from our laboratory [
31] revealed that EBNA1 increases the level of ATF-2 transcription and that it is present at the promoter of the gene. Using shRNA, in the current work we show that by reducing ATF-2 transcripts, levels of both EBERs are reduced significantly in EBV-infected Ad/AH cells (Figure
9a). This supports the previous data suggesting the importance of ATF-2 and ATF-2 binding sites upstream of EBER genes to the expression of EBER transcripts. Further, our data illustrating increased levels of both total and phosphorylated (activated) ATF-2 suggest that EBNA1 acts to increase EBER expression both through induction of ATF-2 transcription and the resultant increase in levels of dual-phosphorylated and activated ATF-2.
Through its interaction with TFIIIB, c-Myc can directly activate many cellular pol III-transcribed genes [
41]. This is consistent with the observed decrease in tRNA expression that accompanies c-Myc RNAi (Figure
9b). However, EBER2 appears to be an exception, as it shows little response to RNAi or overexpression of c-Myc, at least in Ad/AH cells (Figure
9b-d). This may reflect the unusual promoter arrangement and factor requirements of EBER genes, which differ from most cellular pol III promoters [
29]. In contrast to EBER2, the upstream regulatory region of EBER1 contains two adjacent E-box DNA sequences that can be bound directly by c-Myc [
21]. By excising a short region containing these motifs, we revealed its requirement for induction by activated MycER (Figure
9d). This contrasts with a previous report that this upstream region has little importance for EBER1 expression in 293 cells [
47]. Differences between cell types or the fact that the earlier work [
47] used a transient transfection assay may be responsible for the discrepancy. Our data suggest that the EBER genes show differential responsiveness to c-Myc due to E-box DNA motifs upstream of the EBER1 promoter. Our results showing upregulation of c-Myc in response to EBNA1 are consistent with the findings of an earlier study [
35]. In contrast, another study [
52] found that expression of EBNA1 led to a reduction in the level of c-Myc. The authors of this latter study [
52] propose that cell- and tissue-specific effects may be responsible for a variety of discordant observations.
Since EBNA1 induces EBER-associated cellular transcription factors, associates with their promoters (Figure
7, [
31]) and has been shown to bind to multiple sites within the human genome [
53], we addressed the possibility of EBNA1 association with multiple EBER-related transcription factors using chromatin pull-down experiments and found EBNA1 to be associated with the promoters of these factors. The presence of EBNA1 at these promoters affords a potential mechanistic insight into EBNA1's mode of action in enhancing expression of EBERs. The nature of the interaction between EBNA1 and upregulated genes is, at present, unknown. However, whilst the EBNA1-binding motif defined in the EBV genome was absent from the promoters that show EBNA1 association, two recent studies have reported that EBNA1 can bind to cellular genomic DNA [
52,
53]. Further, Canaan et al. [
52] identified several, hitherto uncharacterised EBNA1 DNA binding motifs present in the promoter regions of cellular genes. We found that two of these, WTACTTT and GRAGTATY were present within 1 kb of the transcriptional start sites of the EBNA1-associated ATF2, c-Myc, TFIIIC220 and TFIIIC90 promoters (compatible with the resolution of detection in our ChIP assays). In contrast, these motifs are not present in the promoters of c-Jun or the other TFIIIC subunits whose expression was found to be up-regulated in EBNA1 expressing cells and for which HaloChIP assays indicated EBNA1 binding at their promoters. It is possible that EBNA1's interaction with cellular promoters may be direct in some instances yet indirect in others. Elucidating the mechanisms by which EBNA1 associates with different cellular promoters warrants further investigation.
Although our data indicate that EBNA1, through a variety of mechanisms can induce EBER expression, we note that the levels of expression in this model system are low when compared with those in Ad/AH cells stably infected with EBV. This may be attributable to the EBER expression plasmids in the model system being maintained in an integrated form. In this context it is notable that the Namalwa cell line, in which EBV is known to be integrated at low copy number [
54], also expresses the EBERs at low levels [
18,
55], similar to those seen in our model system (Figure
8b). In the context of whole virus infection, the EBV genome is usually maintained as a multi-copy episome. In this scenario, transcription factor binding access and kinetics may be very different, given that the EBER genes are adjacent to
oriP, within the region of unusual chromatin structure [
47]. The
oriP region (absent from the Ad/AH-EBER cell line) is also known to be a transcriptional enhancer region [
32,
34] and has been previously demonstrated to increase EBER expression by 2- to 4-fold [
47]. The number of copies of the EBER genes integrated into the Ad/AH-EBER cell line generated is unknown, though it is unlikely to reach the number of viral episomes carried by EBV-infected Ad/AH cells. Further, it is of note that EBNA1 does not seem to be capable of inducing TFIIIB subunit expression. We anticipate that pol III-transcribed genes (such as the EBERs) would be even more highly expressed in cells in which TFIIIB was induced in addition to TFIIIC, an environment which is observed in EBV-infected cells [
29].
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
TJO participated in the design and interpretation of the study, carried out the majority of the experimental work and helped to draft the manuscript. JDO participated in the design and interpretation of the study, carried out some HaloChIP work and helped to draft the manuscript. CWD participated in the design and interpretation of the study. CH performed microarray work. XC and YY collected biopsies, performed tumour diagnosis and carried out immunohistochemical staining. VHJW derived cell lines and helped to draft the manuscript. LEM performed western blotting. RJW participated in the interpretation of the study and helped to draft the manuscript. LSY participated in the design and interpretation of the study. JRA participated in the design and interpretation of the study, carried out microarray work and helped to draft the manuscript. All authors read and approved the final manuscript.